Business
ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsight
The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management h
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"ObesityWeek 2025, held in Atlanta from November 4-7, showcased unprecedented clinical data that signals a fundamental shift in the obesity treatment landscape. The most striking breakthrough at ObesityWeek 2025 came from next-generation combination therapies and innovative approaches addressing treatment limitations that have plagued earlier interventions. ","length":358,"tagName":"p"},{"type":"text","content":"LAS VEGAS, Nov. 13, 2025 /PRNewswire/ -- The annual conference presented over 100 scientific sessions featuring innovations from leading pharmaceutical companies, including Novo Nordisk, Eli Lilly and Company, Viking Therapeutics, Ascletis Pharma, Skye Bioscience, Palatin Technologies, Inc., Neurogastrx, Inc., OrsoBio, Metsera, and others, revealing not only significant advances in drug efficacy but also reshaping the multibillion-dollar obesity therapeutics market. These presentations collectively demonstrate that obesity management has matured from a niche pharmaceutical focus into a major healthcare and commercial priority.","length":639,"tagName":"p"},{"type":"image","alt":"DelveInsight_Logo","displaySize":"","headline":null,"caption":"DelveInsight_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":181,"url":"https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Eyi6JBwtj.guENW.piLYXg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9711e6be91b3534a074e21a35fd57d95","width":400,"height":181}}},{"type":"text","content":"Download the updated obesity market report featuring key results from ObesityWeek 2025 @ Anti-Obesity Market","length":108,"tagName":"p"},{"type":"text","content":"Let's dive deep into the promising results presented at the ObesityWeek 2025 ","length":80,"tagName":"p"},{"type":"text","content":"Novo Nordisk's CagriSema: Dual and Multi-Agonist Dominance","length":62,"tagName":"p"},{"type":"text","content":"The most impactful findings centered on dual agonist therapies. CagriSema, Novo Nordisk's once-weekly injection combining cagrilintide (an amylin analogue) with semaglutide (a GLP-1 receptor agonist), demonstrated superiority over monotherapy in the REDEFINE 5 trial presented at the conference. In 331 Asian participants...